Biotechnology

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...

2024-03-19 10:24 622

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

SHANGHAI, March 18, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tec...

2024-03-19 08:00 636

Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)

ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2024-03-19 08:00 803

Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal

* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer SEOUL, South Korea, March 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...

2024-03-18 21:00 1020

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...

2024-03-18 20:32 1097

EDAN and GH Labs Collaborate to Develop AI-Enabled Ultrasound Devices

BELLEVUE, Wash., March 18, 2024 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading global provider of medical and healthcare solutions, announces a collaboration with Global Health Labs, Inc. (GH Labs) to co-develop AI-enabled ultrasound devices. The ...

2024-03-18 19:45 926

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...

2024-03-18 19:25 886

KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1

-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from the pivotal Phase 2 study SHANGHAI, March 18, 2024 /PRNewswire/ -- KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule ...

2024-03-18 18:02 889

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

SHANGHAI, March 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened i...

2024-03-18 09:00 1304

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Can...

2024-03-15 18:00 1925

Novartis expands its biopharmaceutical manufacturing site in Singapore

* Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market  * Set to generate 100 high skilled employment opportunities in Singapore's life science industry  SINGAPORE, March 15, 2024 /PRNewswire/ -- Novartis today...

2024-03-15 14:55 2745

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous ...

2024-03-15 13:56 1225

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

* 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases * Awardees representing 12 countries in Europe, the Americas, Asia and Africa , will receive research grants of up toUSD 600,000 per project * As part of the Seegene's...

2024-03-15 13:41 1869

Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates

ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's le...

2024-03-15 12:34 1163

CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. * This marks the 13th NDA approval obtained by CStone and sugemalimab's fifth indication approved inChina, following stage III and IV no...

2024-03-15 12:10 1891

Angel Yeast Hosts Community Welfare Activity in Egypt, Promoting Green Development and Cultural Exchanges

SHANGHAI, March 15, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, recently hosted a community Welfare Activity on sustainable and green development for the students at a school near its factory inEgypt and gave gifts to the stude...

2024-03-15 09:04 2607

Advancing Healthcare in Uzbekistan: BGI Genomics CEO's Vision Shared on Uzbekistan's National Television

HONG KONG, March 15, 2024 /PRNewswire/ -- Zhao Lijian, CEO of BGI Genomics, provided fresh insights on the company's vision during an exclusive interview withUzbekistan's National Television on Channel O'zbekiston24. This discussion was part of the "Focusing on the History of Uzbekistan-China Rel...

2024-03-15 07:55 1946

I-Mab Reports Full Year 2023 Financial Results and Business Update

* Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end ofMarch 2024 * Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inh...

2024-03-15 05:00 2684

D3 Bio Appoints Dr. Antoine Yver as Independent Board Member

SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, welcomesAntoine Yver, MD. ,MSc. as the new independent board member, effectiveMarch 4, 2024. Dr. Yver has 34 years of e...

2024-03-14 22:30 1464

Virtus Medical Group Announces New Strategic Investors

Shanghai Healthcare Capital, along with Mitsui and MediTrust, invest in and partner strategically with Virtus, cementing Virtus'sLeadership in Private  Healthcare Services, and Propelling Healthcare Innovation. HONG KONG, March 14, 2024 /PRNewswire/ -- Virtus Medical Holdings Limited ("Virtus Med...

2024-03-14 19:43 2142
12345 ... 274